BIO Deutschland English News

Shareable Insights by Citeline | 30. October 2024 Telmisartan Leads UK Rises In September As Price Surges Subside •Who should read this? Anyone with an interest in UK generics pricing and market trends. •What is it? The latest UK pricing information from WaveData looking at data for September. •Why is it important? Generics Bulletin's Pricewatch UK feature has in the past few months reflected numerous products that have seen their average prices more than double. However, the latest data suggests that these extreme rises slowed somewhat in September, while our table of recently-launched generics highlights some significant price movements among certain products that are new to the market.

Shareable Insights by Citeline | 29. October 2024 Gaming Out The Scenarios For Cagrisema And MariTide •Who should read this? Competitive and portfolio intelligence professionals in pharma and biotech companies active in the cardiometabolic space (notably diabetes and obesity); R&D strategy decision-makers and BD&L execs. •What is it? A review of two hotly tipped pipeline obesity drugs with important clinical trial readouts expected by the end of 2024. •Why is it important? The two products are forecast to have sales of $21bn and $4.2bn by 2030. The results will have a big impact on the outlook for their developers, Novo Nordisk and Amgen, and also on the other candidates vying for a stake in the burgeoning and highly lucrative market for obesity.

Shareable Insights by Citeline | 24. October 2024, Part 1 Source: Scrip 𝐀𝐬 𝐒𝐭𝐞𝐥𝐚𝐫𝐚 𝐒𝐮𝐧𝐬𝐞𝐭 𝐁𝐞𝐠𝐢𝐧𝐬, 𝐉&𝐉 𝐒𝐚𝐲𝐬 𝐓𝐫𝐞𝐦𝐟𝐲𝐚 𝐖𝐢𝐥𝐥 𝐒𝐭𝐞𝐩 𝐔𝐩 𝐖𝐡𝐨 𝐬𝐡𝐨𝐮𝐥𝐝 𝐫𝐞𝐚𝐝 𝐭𝐡𝐢𝐬? Portfolio strategy, market intelligence and commercial executives in pharma companies. 𝐖𝐡𝐚𝐭 𝐢𝐬 𝐢𝐭? Analysis of Johnson & Johnson’s Q3 financial results as it faces biosimilar erosion of the formerly best-selling blockbuster inflammatory disease drug Stelara. 𝐖𝐡𝐲 𝐝𝐨𝐞𝐬 𝐢𝐭 𝐦𝐚𝐭𝐭𝐞𝐫? #biosimilar erosion of antibody drugs in this therapeutic category have hit or are about to hit multiple multi-billion dollar drugs in big pharma portfolios. How they replace the lost sales and soften the blow as they lose exclusivity is important information for competitors, and may also have an impact on other patent-protected and pipeline drugs for the same diseases. https://lnkd.in/dUjNwPPw

Shareable Insights by Citeline | 24. October 2024, Part 4 Source: Pink Sheet 𝐍𝐞𝐰 𝐆𝐞𝐫𝐦𝐚𝐧 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐋𝐚𝐰 𝐅𝐚𝐢𝐥𝐬 𝐓𝐨 𝐒𝐭𝐨𝐩 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐅𝐫𝐨𝐦 𝐎𝐩𝐭𝐢𝐧𝐠 𝐎𝐮𝐭 𝐎𝐟 𝐓𝐡𝐞 𝐌𝐚𝐫𝐤𝐞𝐭 𝐖𝐡𝐨 𝐬𝐡𝐨𝐮𝐥𝐝 𝐫𝐞𝐚𝐝 𝐭𝐡𝐢𝐬? Reimbursement and R&D execs considering the German market. 𝐖𝐡𝐚𝐭 𝐢𝐬 𝐢𝐭? A new law in Germany aims to address “flaws” in the pricing system that are discouraging small and medium-sized companies from launching products. 𝐖𝐡𝐲 𝐢𝐬 𝐢𝐭 𝐢𝐦𝐩𝐨𝐫𝐭𝐚𝐧𝐭? The law aims to encourage firms to conduct research in Germany by waiving pricing provisions if they do, but if the incentives prove insufficient, new policies might be considered. https://lnkd.in/dDPcBbj7

Shareable Insights by Citeline | 24. October 2024, Part 3 Source: Medtech Insight 𝐈𝐧𝐛𝐫𝐚𝐢𝐧 𝐇𝐚𝐬 𝐒𝐢𝐠𝐡𝐭𝐬 𝐎𝐧 𝐏𝐚𝐫𝐤𝐢𝐧𝐬𝐨𝐧’𝐬 𝐅𝐨𝐥𝐥𝐨𝐰𝐢𝐧𝐠 𝐅𝐢𝐫𝐬𝐭-𝐈𝐧-𝐇𝐮𝐦𝐚𝐧 𝐓𝐞𝐬𝐭 𝐎𝐟 𝐆𝐫𝐚𝐩𝐡𝐞𝐧𝐞-𝐁𝐚𝐬𝐞𝐝 𝐈𝐦𝐩𝐥𝐚𝐧𝐭 𝐖𝐡𝐨 𝐬𝐡𝐨𝐮𝐥𝐝 𝐫𝐞𝐚𝐝 𝐭𝐡𝐢𝐬? Anyone working in neurology, on brain computer interfaces, and Parkinson’s and exploration of using graphene-based technologies in medicine. 𝐖𝐡𝐚𝐭 𝐢𝐬 𝐢𝐭? An interview with Inbrain’s CEO Carolina Aguilar about the first ever use of a graphene-based brain-computer interface during surgery, her plans for the planned up to 10-patient trial, the development of two different interfaces to target biomarkers involved in movement intention to treat Parkinson’s and other neurological disorders. 𝐖𝐡𝐲 𝐢𝐬 𝐢𝐭 𝐢𝐦𝐩𝐨𝐫𝐭𝐚𝐧𝐭? BCI development is a growing trend and Inbrain wants to be part of it with a unique graphene-based BCI that is expected to have benefits of over currently materials, but still has to pass the safety and efficacy test. https://lnkd.in/dd5nyt3a

Shareable Insights by Citeline | 24. October 2024, Part 2 Source: In Vivo 𝐅𝐮𝐬𝐢𝐨𝐧 𝐂𝐄𝐎 𝐓𝐚𝐥𝐤𝐬 𝐀𝐙 𝐃𝐞𝐚𝐥 𝐌𝐚𝐤𝐢𝐧𝐠 𝐀𝐧𝐝 𝐂𝐚𝐧𝐚𝐝𝐚’𝐬 𝐁𝐥𝐨𝐬𝐬𝐨𝐦𝐢𝐧𝐠 𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐄𝐜𝐨𝐬𝐲𝐬𝐭𝐞𝐦 𝐖𝐡𝐨 𝐬𝐡𝐨𝐮𝐥𝐝 𝐫𝐞𝐚𝐝 𝐭𝐡𝐢𝐬? BD&L executives, R&D leaders in companies in the oncology and radiopharmaceuticals fields. 𝐖𝐡𝐚𝐭 𝐢𝐬 𝐢𝐭? An interview with John Valliant, CEO of a radiopharmaceuticals developer that was acquired by AstraZeneca for $2bn earlier this year. 𝐖𝐡𝐲 𝐢𝐬 𝐢𝐭 𝐢𝐦𝐩𝐨𝐫𝐭𝐚𝐧𝐭? Fusion operates in a development area that has seen a lot of big-ticket pharma deal-making, so it is useful for BD&L executives both at biotech companies and big pharma to hear the behind-the-scenes story on how the deal came together. He also provides insights into the growing ecosystem of companies in this space in Canada. https://lnkd.in/dN5kaYyG

Are you taking part in BIO-Europe in Stockholm this year or would you like to take part but are unable to do so and therefore cannot represent your company? Then as a BIO Deutschland member you now have the chance! We offer our members the opportunity to present their company in the form of a short one-page presentation at BIO-Europe without being present themselves - we will take your presentation with us! With the help of a screen presentation, the company logo as well as a short portrait, e.g. with research focal points, co-operation wishes or service offer should be shown - gladly and due to the international character of BIO-Europe in English.   Please contact hoepner@biodeutschland.org to receive a template, which you can then fill with your information.   We would be very pleased if we could support you with this offer.   Your BIO Deutschland team

Shareable Insights by Citeline | 11 October 2024, Part 4 Source: Generics Bulletin ‘𝗤𝘂𝗶𝗲𝘁 𝗚𝗶𝗮𝗻𝘁’ 𝗕𝗶𝗼𝗰𝗼𝗻 𝗦𝗲𝘁𝘀 𝗢𝘂𝘁 𝗩𝗶𝘀𝗶𝗼𝗻 𝗙𝗼𝗿 𝗕𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿𝘀 𝗪𝗵𝗼 𝘀𝗵𝗼𝘂𝗹𝗱 𝗿𝗲𝗮𝗱 𝘁𝗵𝗶𝘀? Anyone with an interest in #biosimilars market trends in the US and Europe. 𝗪𝗵𝗮𝘁 𝗶𝘀 𝗶𝘁? An interview with Biocon Biologics chief commercial officer for advanced markets Matt Erick about the firm's strategic priorities in biosimilars. 𝗪𝗵𝘆 𝗶𝘀 𝗶𝘁 𝗶𝗺𝗽𝗼𝗿𝘁𝗮𝗻𝘁? When Biocon Biologics absorbed the biosimilars front-end business of former partner Viatris in a multi-billion-dollar deal, it became one of the world's biggest end-to-end biosimilars suppliers. This exclusive interview, taking place around a year after the acquired business was fully integrated in US and Europe, sees chief commercial officer for advanced markets Matt Erick talk about the firm’s plans to grow in untapped European markets, explore in-licensing of biosimilars along with its existing in-house development, and capitalize on the upcoming loss of exclusivity for Stelara in the US, as well as providing an update on compliance issues that have been holding up certain FDA approvals. https://lnkd.in/dFcWwGsD

Shareable Insights by Citeline | 11 October 2024, Part 3 Source: Pink Sheet 𝗖𝗵𝗶𝗻𝗮 𝗠𝗼𝘃𝗲𝘀 𝗙𝗿𝗼𝗺 𝗔𝗱𝗺𝗶𝗻𝗶𝘀𝘁𝗿𝗮𝘁𝗶𝘃𝗲 𝗢𝗿𝗱𝗲𝗿𝘀 𝗧𝗼 𝗠𝗲𝗱𝘁𝗲𝗰𝗵 𝗟𝗮𝘄 – 𝗖𝗼𝗻𝘀𝘂𝗹𝘁𝗮𝘁𝗶𝗼𝗻 𝗨𝗻𝗱𝗲𝗿𝘄𝗮𝘆 𝗪𝗵𝗼 𝘀𝗵𝗼𝘂𝗹𝗱 𝗿𝗲𝗮𝗱 𝘁𝗵𝗶𝘀? Execs at firms with products that may be subject to the US #Medicare price negotiation process. 𝗪𝗵𝗮𝘁 𝗶𝘀 𝗶𝘁? Consultants reflect on the lessons from the first round of negotiation. 𝗪𝗵𝘆 𝗶𝘀 𝗶𝘁 𝗶𝗺𝗽𝗼𝗿𝘁𝗮𝗻𝘁? With the second round approaching, sponsors of products that are selected will want to set appropriate expectations internally. https://lnkd.in/dRVcZEt2

Shareable Insights by Citeline | 11 October 2024, Part 2 Source: Medtech Insight 𝗖𝗵𝗶𝗻𝗮 𝗠𝗼𝘃𝗲𝘀 𝗙𝗿𝗼𝗺 𝗔𝗱𝗺𝗶𝗻𝗶𝘀𝘁𝗿𝗮𝘁𝗶𝘃𝗲 𝗢𝗿𝗱𝗲𝗿𝘀 𝗧𝗼 𝗠𝗲𝗱𝘁𝗲𝗰𝗵 𝗟𝗮𝘄 – 𝗖𝗼𝗻𝘀𝘂𝗹𝘁𝗮𝘁𝗶𝗼𝗻 𝗨𝗻𝗱𝗲𝗿𝘄𝗮𝘆 𝗪𝗵𝗼 𝘀𝗵𝗼𝘂𝗹𝗱 𝗿𝗲𝗮𝗱 𝘁𝗵𝗶𝘀? Regulatory executives and business development departments within innovative medtechs who need to keep #China in their global market access footprint. 𝗪𝗵𝗮𝘁 𝗶𝘀 𝗶𝘁? Notice of a Chinese Medical Device Administrative Law in 2025, which, after two decades of medical device administrative orders, will put medtech on the same level as pharma. 𝗪𝗵𝘆 𝗶𝘀 𝗶𝘁 𝗶𝗺𝗽𝗼𝗿𝘁𝗮𝗻𝘁? Going broader than regulatory – but not touching on volume-based procurement – the law will necessarily change the behaviours of market entrants by introducing broader liability for local Chinese agents; stipulating adherence to standards; and imposing larger penalties for noncompliance. But more favorable reimbursement mechanisms for innovative products and encouraging hospitals to procure them are also proposed. https://lnkd.in/dqrkTa4W